Reinmuth N - Search Results

1

[Management of adverse events in immune oncology - Practical aspects of immune-related adverse events during immune oncological treatment].

Reinmuth N, Bitzer M, Deschler-Baier B, Fischer JR, Kuon J, Leipe J, Rawluk J, Schulz C, Heußel CP, Schultheiß M. Reinmuth N, et al. Dtsch Med Wochenschr. 2019 Mar;144(5):346-353. doi: 10.1055/a-0739-8194. Epub 2019 Jan 30. Dtsch Med Wochenschr. 2019. PMID: 30699440 Review. German.

2

Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden.

Paz-Ares L, Garassino MC, Chen Y, Reinmuth N, Hotta K, Poltoratskiy A, Trukhin D, Hochmair MJ, Özgüroğlu M, Ji JH, Statsenko G, Conev N, Bondarenko I, Havel L, Losonczy G, Xie M, Lai Z, Godin-Heymann N, Mann H, Jiang H, Shrestha Y, Goldman JW. Paz-Ares L, et al. Among authors: reinmuth n. Clin Cancer Res. 2024 Feb 16;30(4):824-835. doi: 10.1158/1078-0432.CCR-23-1689. Clin Cancer Res. 2024. PMID: 37801329 Free PMC article. Clinical Trial.

3

Rationale and Design of the Phase II ANTELOPE Study of Atezolizumab, Carboplatin and nab-Paclitaxel vs. Pembrolizumab, Platinum and Pemetrexed in TTF-1 Negative, Metastatic Lung Adenocarcinoma (AIO-TRK-0122).

Frost N, Bleckmann A, Griesinger F, Grohé C, Janning M, Kollmeier J, Reinmuth N, Sebastian M, Thomas M, Reck M. Frost N, et al. Among authors: reinmuth n. Clin Lung Cancer. 2023 Sep;24(6):568-572. doi: 10.1016/j.cllc.2023.04.009. Epub 2023 Apr 23. Clin Lung Cancer. 2023. PMID: 37169628 Clinical Trial.

4

Concurrent/sequential versus sequential immune checkpoint inhibition in inoperable large stage III non-small cell lung cancer patients treated with chemoradiotherapy: a prospective observational study.

Käsmann L, Eze C, Taugner J, Nieto A, Hofstetter K, Kröninger S, Guggenberger J, Kenndoff S, Flörsch B, Tufman A, Reinmuth N, Duell T, Belka C, Manapov F. Käsmann L, et al. Among authors: reinmuth n. J Cancer Res Clin Oncol. 2023 Aug;149(10):7393-7403. doi: 10.1007/s00432-023-04654-w. Epub 2023 Mar 20. J Cancer Res Clin Oncol. 2023. PMID: 36939927 Free PMC article.

5

Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions.

Hassel JC, Heinzerling L, Aberle J, Bähr O, Eigentler TK, Grimm MO, Grünwald V, Leipe J, Reinmuth N, Tietze JK, Trojan J, Zimmer L, Gutzmer R. Hassel JC, et al. Among authors: reinmuth n. Cancer Treat Rev. 2017 Jun;57:36-49. doi: 10.1016/j.ctrv.2017.05.003. Epub 2017 May 18. Cancer Treat Rev. 2017. PMID: 28550712 Review.

6

Polymorphisms in the apoptotic pathway gene BCL-2 and survival in small cell lung cancer.

Knoefel LF, Werle-Schneider G, Dally H, Müller PJ, Edler L, Bartsch H, Tuengerthal S, Heussel CP, Reinmuth N, Thomas M, Risch A. Knoefel LF, et al. Among authors: reinmuth n. J Thorac Oncol. 2011 Jan;6(1):183-9. doi: 10.1097/JTO.0b013e3181f8a20e. J Thorac Oncol. 2011. PMID: 21107291 Free article.

7

Impact and safety of adjuvant chemotherapy on pulmonary function in early stage non-small cell lung cancer.

Kreuter M, Vansteenkiste J, Herth FJ, Fischer JR, Eberhardt W, Zuna I, Reinmuth N, Griesinger F, Thomas M; TREAT investigators. Kreuter M, et al. Among authors: reinmuth n. Respiration. 2014;87(3):204-10. doi: 10.1159/000355361. Epub 2013 Oct 30. Respiration. 2014. PMID: 24192055 Clinical Trial.

8

[Non-small cell lung cancer: news from immunotherapy].

Reinmuth N, Heigener DF, Reck M. Reinmuth N, et al. Dtsch Med Wochenschr. 2015 Mar;140(5):329-33. doi: 10.1055/s-0041-100763. Epub 2015 Mar 3. Dtsch Med Wochenschr. 2015. PMID: 25734674 Review. German.

9

Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy.

Eigentler TK, Hassel JC, Berking C, Aberle J, Bachmann O, Grünwald V, Kähler KC, Loquai C, Reinmuth N, Steins M, Zimmer L, Sendl A, Gutzmer R. Eigentler TK, et al. Among authors: reinmuth n. Cancer Treat Rev. 2016 Apr;45:7-18. doi: 10.1016/j.ctrv.2016.02.003. Epub 2016 Feb 18. Cancer Treat Rev. 2016. PMID: 26922661 Review.

10

ERCC1 assessment in upfront treatment with and without cisplatin-based chemotherapy in stage IIIB/IV non-squamous non-small cell lung cancer.

Villalobos M, Czapiewski P, Reinmuth N, Fischer JR, Andreas S, Kortsik C, Serke M, Wolf M, Neuser P, Reuss A, Schnabel PA, Thomas M. Villalobos M, et al. Among authors: reinmuth n. Med Oncol. 2018 Jun 15;35(7):106. doi: 10.1007/s12032-018-1169-5. Med Oncol. 2018. PMID: 29905882 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

167 results

Search Page

Filters